 Caribou Biosciences, Inc. NASDAQ: CRBU shares are trading lower after the company reported additional data from its CB-010 allogeneic CAR-T cell therapy Phase 1 ANTLER trial at the European Hematology Association 2022 Hybrid Congress. A 100 complete response rate 6 of 6 patients was. 